Objective: Peripheral arterial disease (PAD) is a highly prevalent condition that contributes significantly to the morbidity and mortality of affected patients. PAD creates a significant economic burden on health care systems around the world. We reviewed all available literature to provide a meta-analysis assessing the outcome of patients treated with drug-eluting balloons (DEBs) compared with percutaneous transluminal balloon angioplasty (PTA) through measuring the rate of target lesion revascularization (TLR).
Peripheral arterial disease (PAD) is a highly prevalent condition affecting the aging population. Several epidemiologic studies have estimated the prevalence of PAD to range from 3% to 10%. 1 This prevalence increases to 15% to 20% in people aged >70 years. 2 There are no national data for PAD prevalence in Australian populations; however, a cross-sectional survey conducted of men from metropolitan Perth found an age standardized prevalence of 15.6%. 3 PAD contributes significantly to the morbidity and mortality of adults as well as being a significant economic burden. 4 United States data from the REACH (Reduction of Atherothrombosis for Continued Health) registry demonstrated that patients with PAD had the highest rates of fatal myocardial infarction compared with coronary artery disease (CAD) and cerebrovascular disease populations. 5, 6 The total annual cost for vascular-related hospitalizations for patients with PAD in the United States is estimated to exceed $21 billion. 6 The average annual cost per patient with diagnosed PAD is estimated to range from 1741 to 3559 in France and from 1005 to 1516 in Germany. 7 This magnitude of expenditure is equal, if not greater, than estimates of annual hospital costs associated with type 2 diabetes mellitus. 8 The high hospitalization costs for patients with PAD are the result of high rates of initial and repeat revascularization procedures. 7 An endovascular peripheral arterial revascularization procedure is any intervention involving insertion of a guidewire into a peripheral artery. Repeat revascularization procedures are termed target lesion revascularization (TLR).
They involve repeat percutaneous intervention of the target lesion or surgical bypass of the target vessel performed for restenosis. 9 Lesions in the superficial femoral artery and popliteal artery are conventionally treated with percutaneous transluminal balloon angioplasty (PTA). 10 However, this procedure has demonstrated poor efficacy at midterm follow-up, with 40% to 60% of patients requiring reintervention #12 months. 10 Stent implantation appears to be an attractive alternative due to the success this method has achieved in reducing rates of reintervention in patients with CAD. 11 Unfortunately, the use of stents in peripheral arteries leads to an inflammatory response that produces neointimal hyperplasia and results in restenosis. Although the precise mechanism is not known, the metal mesh and polymer coating of the stent are hypothesized to exert an inflammatory stimulus on the vessel. 12 Drug-eluting balloons (DEBs) are a relatively new treatment option that enables mechanical dilation of the artery as well as delivery of antiproliferative drugs. One notable example is paclitaxel. 12 The presence of paclitaxel inhibits neointimal formation and is hypothesized to maintain artery patency at midterm follow-up. The efficacy and safety of the cytotoxic and antiproliferative effect of paclitaxel has been thoroughly investigated in the literature through in vitro models, animal models, and clinical trials. [13] [14] [15] Previous studies have demonstrated an increased short-term efficacy of DEBs compared with PTA. 16 However, the short follow-up intervals in these studies limited the effect of their results. Currently, the efficacy of DEBs compared with PTA in maintaining patency and reducing reintervention rates in PAD is unknown. As previously mentioned, reducing the reintervention rate in patients with PAD would have substantial implications on hospitalization costs. We conducted a meta-analysis to collate the current evidence investigating the use of DEBs in PAD. This report reviews all available literature and provides a meta-analysis of all trials involving DEBs. Primarily, this meta-analysis assesses the outcome of patients treated with DEBs compared with PTA through measuring the rate of TLR. Secondary end points include late lumen loss (LLL), BR, primary patency, rates of bailout stenting, death, and amputation.
METHODS
Literature search. A search strategy was devised according to the 2009 Preferred Reporting Items of Systematic Reviews and Meta-Analyses statement. An electronic search of the MEDLINE, Scopus, Embase, Web of Science, and Cochrane Library databases was performed from inception to July 26, 2015, with no language restrictions.
To identify studies investigating the difference in outcomes when comparing DEBs vs PTA, the following search terms were applied: (Arteriosclerosis or Peripheral Arterial Disease or Peripheral Vascular Disease or Arterial Occlusive Disease) and (angioplasty or balloon angioplasty or endovascular procedures) and (paclitaxel) with prior checking in the Medical Subject Heading database to include synonyms.
The database search was supplemented by a search of the reference lists of included studies and by using the related-articles function provided in each database. Titles and abstracts were screened to identify potentially relevant studies. If the suitability of an article was uncertain, the full-text article was reviewed. All potentially relevant studies were subsequently assessed by review of the full-text articles.
Eligible studies were those that (1) assessed the outcome of DEB use in patients with PAD in the femoropopliteal arteries (FPA), (2) contained a randomized design where PTA was the control, and (3) reported patient follow-up from at least 6 months. Only publications in English were included.
Studies were excluded when (1) the primary focus was CAD, carotid artery disease, aortic aneurysmal disease, or intracranial vascular disease, (2) patients treated with DEBs were not the primary focus of the report, (3) patients were treated with DEBs combined with other surgical interventions, (4) or the focus of the trial was to assess the efficacy of DEB use in treating in-stent restenosis or graft stenosis.
Data extraction. Data extraction was performed according to a predefined form and recorded in tables. All data were reviewed independently by two authors (N.C., E.N.) and cross-checked in a consensus meeting. Any discrepancies were resolved through discussions.
The following data were obtained from the included studies: study design, sample size, inclusion and exclusion criteria, primary, secondary, and safety end points, follow-up intervals, patient age, sex, and smoking status, comorbidities, such as hypertension, CAD, hyperlipidemia, diabetes, and renal dysfunction, baseline ankle-brachial index (ABI) and Rutherford classification, presence of patent run-off vessels, number of lesions, lesion length, type, and location, degree of calcification, reference vessel diameter, diameter stenosis, total occlusion, bailout stenting, procedural success and at follow-up, rates of death, amputation, TLR, primary patency, BR, minimum lumen diameter, late lumen loss (LLL), change in Rutherford class and ABI, and secondary patency. The end point definitions with type and incidence of events were recorded. The method of statistical analysis and subsequent results were also recorded.
Data were standardized to include event numbers and percentages of the relevant study population, where possible. Potential sources of bias or conflict of interest were recorded. Authors were contacted for additional information when required. 17, 18 Quality assessment. We used a modified quality assessment tool incorporating elements of the Jadad scale and Cochrane Collaboration tool to assess the methodological quality and risk of bias of the included studies. 19, 20 The quality assessment tool assessed study design, patients selected, intervention details, follow-up, and outcome measures (Supplementary Table I , online only). The same two independent investigators evaluated the risk of bias in the individual studies using the Cochrane Collaboration method. Discrepancies in individual study outcomes were resolved by discussion between authors N.C. and E.N.
Statistical analysis. Statistical analysis was performed with Review Manager 5.2 (Cochrane Collaboration, Copenhagen, Denmark). 21 Mean differences, odds ratios (ORs), and 95% confidence intervals (CI) were calculated for each included study. Study-specific estimates were combined using inverse-variance weighted average of logarithmic mean differences and Mantel-Haenszel ORs in random fixed-effects models. Random-effects models were chosen to minimize the effect of heterogeneity on the summary statistics. To ensure significance, fixedeffects models were also calculated to determine whether there was a significant change in the measured effect estimate. Interstudy heterogeneity was assessed by means of the I 2 index. I 2 values of >50% were accepted to denote statistical heterogeneity. Sensitivity analyses were performed using the one-study-removal approach to assess the contribution of each study to the combined effect. Publication bias was assessed by constructing funnel plots of the logarithm of effect size vs the standard error.
RESULTS
Study selection. From the literature search, 549 articles were identified through searching the MEDLINE, Scopus, Embase, Web of Science, and Cochrane Library databases (Fig 1) . One additional article 17 was identified through searching reference lists. After duplicates had been removed, 506 articles were screened, with 492 excluded by the content of the title or the abstract. The most common reasons for exclusion were the primary ). Information regarding baseline lesion and procedural characteristics for each included article can be found in Table I .
Data regarding TLR was reported at various follow-up intervals between articles due to differences in study design and lack of standardization regarding time intervals for appropriate follow-up (Tables II-IV) . Six-month follow-up data were extracted from two articles. 17, 18 One article 18 reported 6-month follow-up data for TLR;
however, it was reported as TLR per limb rather than per patient, and the analysis excluded the TLR data from this article. One article 17 provided 6-month followup data for TLR as Kaplan-Meier curves. Only secondary safety end points from this article 17 were included in the analysis because they were the outcomes of interest. Two articles 24, 29 reported TLR rates in 6-and 12-month follow-up data. The 6-, 12-, and 24-month follow-up data regarding TLR was extracted from two articles, 22, 25 6-and 24-month follow-up data pertaining to TLR were extracted from one article, 23 and 12-month follow-up data were extracted from two articles. 26, 27 Finally, 60-month data were extracted from one article. 28 All articles reported prescribing aspirin and clopidogrel postoperatively. 17, 18, [22] [23] [24] [25] [26] [27] [28] [29] The aspirin dose ranged from 81 to 325 mg, with 100 mg being the most common. 18, [22] [23] [24] In seven articles 18,22-27 the clopidogrel dose was 75 mg once daily, but the three remaining articles 17, 28, 29 did not state the clopidogrel dose.
Findings. Data on LLL was available for 384 lesions at 6 months, with 190 receiving DEB interventions and 194 receiving PTA interventions. 18, [22] [23] [24] [25] 29 A statistically significant reduction in LLL in DEB-treated patients compared with PTA patients was calculated (mean difference, À0.74; 95% CI, À0.97 to À0.51; P < .00001; Fig 2) .
Data on BR was available for 684 lesions at 6 months, with 403 receiving DEB interventions and 281 receiving PTA interventions. 17, [22] [23] [24] 29 A statistically significant decreased rate of BR was demonstrated in patients treated with DEBs compared with PTA (OR, 0.34; 95% CI, 0.23-0.49; P < .00001; Fig 2) .
Data on TLR were available at 6, 12, and 24 months. Rates of TLR were significantly reduced in patients treated with DEBs compared with patients treated with PTA for follow-up at 6 months (OR, 0.24; 95% CI, 0.11-0.53; P ¼ .0004), 12 months (OR, 0.28; 95% CI, 0.13-0.62; P ¼ .002), and 24 months (OR, 0.25; 95% CI, 0.10-0.61; P ¼ .002; Fig 3) . The 6-month data were available for 415 lesions, with 208 lesions treated with DEBs and 207 lesions treated with PTA. [22] [23] [24] [25] 29 A reduction in rates of TLR in DEB patients compared with PTA patients Pooled effect estimates from all included articles on death and amputation did not yield any significant results at 6-, 12-, or 24-month follow-up intervals ( Supplementary Fig 1, online only) .
Study quality. The main findings on study quality can be summarized as the following: (1) overall low study heterogeneity was calculated for data describing LLL, BR, death, amputation, and TLR at 6 months, with high heterogeneity calculated for data describing TLR at 12 and 24 months, (2) overall risk of publication bias was unable to be determined, (3) overall article quality was determined to be high in one article, 27 Supplementary Fig 1, online only) . Sensitivity analyses demonstrated low heterogeneity for the calculated effect of LLL at 6 months, BR at 6 months, and TLR at 6 and 12 months. Sensitivity analyses demonstrated heterogeneity for the calculated effect of TLR at 24 months (Supplementary  Table IV , online only).
Calculation of effect estimates with a random-effects or fixed-effects model did not change the overall outcome or alter the statistical significance of the result.
Funnel plots of the logarithm of effect size vs the standard error were generated from the included articles; however, accurate appraisal was not possible due to the limited number of included studies, variation in outcome measures, subjectivity, and heterogeneity across studies (Supplementary Fig 2, online only) . Data are presented as number of events/total number of patients (%), mean 6 standard deviation, or median (25th percentile; 75th percentile).
Included articles were collated in a quality assessment consensus table to compare methodological items between articles. Quality assessment using the modified assessment tool determined one included article 27 that was determined to be high quality (Table V) because the authors included (1) definite criteria about what constituted TLR, (2) independent and blinded vascular laboratories and ultrasound core laboratories were recruited to analyze quantitative angiographic outcomes, (3) an independent clinical events committee was involved in determining which patients met the criteria for TLR, and (4) different clinicians, who were blinded to patient treatment, were recruited for followup data collection. Seven articles were graded as moderate quality. Common features among these moderate-quality articles included: (1) definition of primary and secondary outcomes, (2) defined follow-up intervals, (3) defined inclusion and exclusion criteria, (4) detailed description of interventions, (5) independent clinical events committees were not involved in selecting patients for TLR, and (6) treating clinicians who were unblinded to patient treatment were involved in patient follow-up. Two articles 17, 28 were graded as low quality. Common features among these low-quality articles 17, 28 included:
(1) baseline lesion characteristics were undefined, (2) the DEB brand and dose was not clearly defined, and (3) outcome measures regarding TLR were not included (Supplementary Table I 
DISCUSSION
The result of this meta-analysis indicates that the use of DEBs in patients with PAD significantly reduced the reintervention rate compared with patients treated with PTA. The main findings can be summarized to the following: (1) the rate of TLR in DEB-treated patients was lower compared with patients treated with PTA at 6, 12, and 24 months, (2) the rate of LLL in DEB-treated patients was lower than in patients treated with PTA at 6 months, (3) the rate of BR in DEB-treated patients was lower compared with patients treated with PTA at 6 months, (4) death and amputation at 6, 12 and 24 months were both noninferior in DEB-treated patients compared with PTA-treated patients, and (5) rates of bailout stenting were increased in PTA-treated patients compared with DEB-treated patients.
Rates of TLR. The finding that patients treated with DEBs led to a statistically significant decreased rate of reintervention is important for a number of reasons. The economic value in reducing the reintervention rate in patients with PAD has been previously elucidated. 2, [5] [6] [7] [8] The result of this meta-analysis indicates that treatment with DEBs leads to significantly reduced reintervention rates over the observed follow-up period.
In fact, one article 28 reported 60-month follow-up data from patients treated through the THUNDER trial. Patients treated with DEBs had statistically significant fewer TLRs (20.8%) than patients treated with PTAs (55.6%; P ¼ .0005). This is the first long-term data on DEB treatment to be published. Therefore, through reducing reintervention rates, DEBs may hypothetically reduce readmission, intervention, and hospital stays. However, specific studies will need to be conducted to determine the cost-effectiveness of DEBs. Apart from PTA, outcomes with DEBs have not been adequately compared with other endovascular therapies.
Rates of LLL and BR. LLL and BR are well-established anatomical measures of treatment efficacy. 34 The results of this meta-analysis demonstrate substantially decreased rates of LLL and BR in patients who were treated with DEBs vs PTA at 6 months after the intervention. 17, 18, [22] [23] [24] [25] 29 One article 28 collected data on LLL and BR at 12 months and 60 months and demonstrated a statistically significant lower rate of BR in DEB-treated patients at 12 and 60 months. In addition, LLL was decreased in patients treated with DEBs at 12 months and 60 months, with significance only being achieved with the 12-month follow-up data. The authors of this article 28 stated their methodology was only powered to investigate LLL at 6 months; therefore, the sample size of patients attending follow-up at 12 and 60 months is small. Nevertheless, the significant positive results at up to 60 months after treatment with DEBs demonstrates their superiority compared with PTA. 28 One article 23 collected data on BR at 24 months that indicated decreased rates of BR in patients treated with DEBs compared with PTA. This measure did not reach significance. LLL and BR are useful measures of device efficacy for comparing DEBs and PTAs through quantifying the degree of restenosis over the short-term. LLL and BR are useful end points in small trials because small sample sizes are able to generate significant results. 35 Future research should involve longer follow-up intervals with end points that are more inclusive then LLL and BR. The combination of safety and efficacy measures, such as major adverse events and TLR, are considered the most comprehensive. 35 However, these end points require
large sample sizes to demonstrate significant results.
Rates of death and amputation. The results of this meta-analysis demonstrate no difference in the rate of death or amputation for patients being treated with DEBs compared with PTA. This result is significant because it indicates that DEB use does not increase mortality or amputation compared with current standard PTA 36 indicates that endovascular interventions, such as PTA, correlate with increased rates of amputation compared with surgical bypass grafts. Therefore, despite this meta-analysis demonstrating no increase in death and amputation compared with PTA, more studies will need to be conducted comparing DEBs vs surgical bypass grafts.
Increased rates of bailout stenting in the control group. This review detected a significantly increased rate of bailout stenting in five articles 17, 22, 25, 27, 29 (four clinical trials) for patients treated with PTA. The significance of this result is that the patients who received bailout stenting were still included in data collection at follow-up because these trials were designed on an intention-to-treat basis. allowed bailout stenting if there was a flow-limiting dissection >50%. All four articles 17, 25, 27, 29 were single blinded or recognized that true blinding was not possible because of the obvious differences in the DEB and PTA device. We believe that clinicians may have been more inclined to provide bailout stenting to a patient treated with PTA if they had borderline rebound stenosis. Whether the increased rates of bailout stenting had an effect on the measured end points in the four trials is unknown 17, 22, 25, 27, 29 Limitations. The main limitations of the included articles can be summarized to the following: (1) the definition of TLR varied among the included articles, (2) heterogeneity existed between TLR data at 12 and 24 months, (3) definition of primary patency varied between included articles, (4) three included articles 18, 24, 29 allowed multiple target lesions per patient, (5) end points assessing functional outcome were not uniformly examined, (6) variation existed in the paclitaxel dose delivered through DEBs, (7) comparison of DEBs to other endovascular treatments, and (8) potential for investigator and sponsor bias cannot be excluded.
The definition of TLR varied slightly between articles. Two articles 17, 27 did not consider bailout stent placement during the index procedure as a TLR, whereas eight articles 18, [22] [23] [24] [25] [26] 28, 29 considered bailout stent placement during the index procedure as a TLR. Three articles 22, 25, 29 provided reintervention based purely on patient symptoms. 34 It was recognized that TLR required two components: luminal stenosis and the clinical status of the patient. These components provided information about the device failure at an anatomical level, whereas clinical status provided a direct reflection of patient outcomes caused by device failure. Heterogeneity existed between articles reporting data for rates of TLR at 12 and 24 months. We believe that the result of heterogeneity is the result of several factors, including the small sample size of the included articles, variations in study design, differences in patient characteristics, and regional differences. However, it has been argued that because clinical and methodological diversity will occur in a meta-analysis, statistical heterogeneity is inevitable. 19 Variation existed between four articles 17, [25] [26] [27] 37 Therefore, future trials should investigate whether the difference in paclitaxel dose alters the clinical outcome for patients. As outlined earlier, sponsor bias and investigator bias cannot be excluded from the included articles. Although this bias may have affected the data presented in these articles, early clinical trials, such as the ones included in this meta-analysis, typically require financial support from a sponsor to generate sufficient data to have a statistically significant outcome.
CONCLUSIONS
This meta-analysis demonstrates that treatment with DEBs compared with PTA result in reduced rates of reintervention in patients with PAD. We have identified the importance of uniform criteria for reintervening in patients with PAD to allow more accurate calculations. Comparison of DEBs with other emerging treatment, such as drug-eluting stents, to determine which method imparts the greatest efficacy should be the focus of future large-scale trials. Improvement in quality of life through assessing functional outcomes, such as change in Rutherford classification and improvement in Walking Impairment Questionnaires, should be a focus of future clinical trials. These trials would allow determination about average quality-adjusted life-years gained. Consequently, an accurate cost-utility analysis could be conducted to accurately determine the incremental cost effectiveness of DEB interventions. Supplementary Fig 1 (online only) . Meta analysis comparing the outcomes of death and amputation at 6, 12, and 24 months between patients treated drug-eluting balloons (DEBs) and percutaneous transluminal angioplasty (PTA). Forest plot demonstrating odds ratios (OR) and 95% confidence intervals (CI; horizontal lines) for the comparison of death in patients treated with DEBs and PTA at 6, 12 and 24 months. The solid squares indicate the mean difference and are proportional to the weights used in the meta-analysis. The diamond represents the total OR calculated in this meta-analysis. Forest plot demonstrating mean difference (OR) with 95% CI (horizontal lines) for the comparison of amputation in patients treated with DEBs and PTA at 6, 12, and 24 months. The solid squares indicate the mean difference and are proportional to the weights used in the meta-analysis. The diamond represents the total OR calculated in this meta-analysis. M-H, Mantel-Haenszel. Did the study match/adjust/exclude confounders?
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Are the patient inclusion criteria clearly defined?
Are the patient exclusion criteria clearly defined?
Are lesion characteristics clearly defined?
Is the patient randomization process clearly defined?
Intervention details Is the type of balloon catheter and commercial product clearly defined?
Is the dose of paclitaxel clearly defined?
Is the intervention procedure clearly defined?
Were the parameters of intervention success clearly defined?
Follow-up Are patient follow-up time points clearly defined?
Are the follow-up procedural details clearly defined?
Are the number of patients that attended each stage of follow-up clearly defined?
Are clearly defined reasons provided for patients who did not attend follow-up?
Are the treating clinicians who were aware of patient treatment involved in follow-up?
Outcome measures Is the primary end point clearly defined?
Are secondary end points clearly defined?
Are safety end points clearly defined?
Are there defined criteria for how patients are selected for TLR?
Is quantitative angiographic follow-up data determined by an independent laboratory blinded to individual patient treatments?
Is an independent clinical events committee involved with selecting patients for TLR? The methodological items were assessed using the assessment tool shown below. Each question was answered "yes" or "no," with a "yes" response scoring 1 point and "no" responses scoring 0, with the exception of question 3 where a "yes" response scored 1 point and a "no" response scored 0.
Points for each methodological item were collated and a quality category of low, moderate, or high was assigned according to the number of points scored. The quality category for each methodological item was used to determine an overall quality score for each included article. High-quality articles were considered to contain all high-quality categories with no more than one moderate-quality category. Moderate-quality articles were considered to contain two or more moderate-quality categories, with no low-quality categories. Low-quality articles included any article with at least one low quality category. Includes patients with diabetes who were "insulin-dependent" or "noninsulin-dependent". c Fontaine classification score. 
